Do Royal Marsden Hospital (RMH) and MD Anderson cancer centre (MDACC) prognostic scoring systems predict survival in patients with Bone sarcoma?

Date 22 October 2018
Event ESMO 2018 Congress
Session Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Topics Bone Sarcomas
Translational Research
Presenter Waleed Alselwi
Citation Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299
Authors W. Alselwi1, F. Azam1, M.F. Latif1, I.A.E. Osman2, W.A.H. Taha2, K. Bawazir2, A. Farooq3, N. Bukhari4, F. Ibnshamsah2
  • 1Medical Oncology, King Fahad Specialist Hospital, 31444 - Dammam/SA
  • 2Adult Medical Oncology, King Fahad Specialist Hospital, 31434 - Dammam/SA
  • 3Internal Medicine, East Lancashire Hospitals NHS Trust, BB102PQ - Burnley/GB
  • 4Adult Medical Oncology, King Fahad Specialist Hospital, Dammam, 31444 - Dammam/SA



There is no specific prognostic scoring system for patients with bone sarcomas. Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems are used for prognostic classification of different malignancies. The purpose of this study is to evaluate different clinical factors and their correlation with poor survival in bone sarcomas.


We retrospectively reviewed clinical files of patients (pts) diagnosed with bone sarcoma at the tertiary Oncology Centre between January 2006 and June 2017. Clinical factors including Serum albumin, serum lactate dehydrogenase (LDH), performance status (PS), number of metastases, (in RMH and MDACC scoring systems), platelet count, hemoglobin (HB), serum creatinine and gender were also evaluated. Data was analyzed using SPSS software.


Total of 87 pts with bone sarcoma were identified of which 33 (38%) pts died. Twenty (61%) pts were males and 13 (39%) pts were females. Median age at the time of diagnosis was 23 (12-83) years. Median overall survival (OS) for the whole group was 12 (1-76) months (mo). Pts presented with metastatic disease had a median OS of 11 mo. Median survival of pts with locoregional disease was 19 mo. On univariate analysis, more than 2 sites of metastases was the only factor associated with poor survival (p = 0.035). On regression analysis the co-efficient between all the variables and survival time is high (R = 0.823) but this is not statistically significant (p = 0.112). There was no statistically significant association between poor survival and low serum albumin, high LDH, poor PS, high platelet count, low HB, high serum creatinine and male gender.


Our study concludes that there is a strong correlation between poor survival and more than 2 metastatic sites in patients with bone sarcomas. Other prognostic factors in RMH and MDACC scoring system were not found to be statistically significant in this study. Further studies are needed to validate these clinical factors.

Clinical trial identification

Legal entity responsible for the study

King Fahad Specialist Hospital, Damman.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.